Abata obtains IND clearance for autologous TCR-Treg therapy for progressive MS
July 10, 2024
Abata Therapeutics Inc. has obtained FDA clearance for its IND application enabling initiation of a first-in-human study of ABA-101 in patients with progressive multiple sclerosis (MS). A phase I study will open later this year.